Renaissance Technologies
BTAI icon

Renaissance Technologies’s BioXcel Therapeutics BTAI Stock Holding History

Renaissance Technologies’s Portfolio BTAI Stock Details BTAI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-4,869
Closed -$29.1K – 3483
2024
Q4 		$29.1K Sell
4,869
-3,248
-40% -$27.1K ﹤0.01% 3455
2024
Q3 		$79.2K Buy
+8,117
New +$109K ﹤0.01% 3293
2024
Q2 		– Sell
-1,482
Closed -$67K – 3521
2024
Q1 		$67K Buy
+1,482
New +$70.7K ﹤0.01% 3437
2023
Q2 		– Sell
-5,875
Closed -$1.75M – 3932
2023
Q1 		$1.75M Buy
+5,875
New +$2.51M ﹤0.01% 2106
2022
Q4 		– Sell
-2,219
Closed -$420K – 4128
2022
Q3 		$420K Sell
2,219
-1,256
-36% -$292K ﹤0.01% 3027
2022
Q2 		$734K Buy
3,475
+2,300
+196% +$484K ﹤0.01% 2908
2022
Q1 		$393K Buy
+1,175
New +$341K ﹤0.01% 3334
2020
Q3 		– Sell
-9,725
Closed -$8.25M – 3389
2020
Q2 		$8.25M Buy
9,725
+5,194
+115% +$3.39M 0.01% 1337
2020
Q1 		$1.62M Sell
4,531
-150
-3% -$53.9K ﹤0.01% 2166
2019
Q4 		$1.09M Sell
4,681
-175
-4% -$17.6K ﹤0.01% 2585
2019
Q3 		$547K Buy
4,856
+381
+9% +$60.1K ﹤0.01% 2836
2019
Q2 		$785K Buy
4,475
+1,675
+60% +$284K ﹤0.01% 2805
2019
Q1 		$443K Buy
+2,800
New +$345K ﹤0.01% 2966

Other funds holding BTAI

M
Murchinson Toronto, Ontario, Canada $791M AUM 68.08% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BPA
Beacon Pointe Advisors Newport Beach, California $18.9B AUM 18.9% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Renaissance Technologies's BTAI Position: Q1 2025 in Review

Renaissance Technologies sold out of BioXcel Therapeutics (BTAI) in Q1 2025, closing a stake of 4,869 shares — an estimated $29.1K sold.

Renaissance Technologies first reported a position in BTAI in Q1 2019 and held it in 13 quarters. The position peaked at $8.25M in Q2 2020. 31 funds tracked by Wall St. Rank hold BTAI as of Q1 2025.

  • Renaissance Technologies reported no remaining BioXcel Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Renaissance Technologies sold 4,869 BioXcel Therapeutics shares in Q1 2025, an estimated $29.1K.
  • Renaissance Technologies first reported a position in BioXcel Therapeutics in Q1 2019 and held it in 13 quarters.
  • Renaissance Technologies's BioXcel Therapeutics position peaked at $8.25M in Q2 2020.
  • 31 funds tracked by Wall St. Rank held BioXcel Therapeutics as of Q1 2025.

Based on Renaissance Technologies's 13F filing for Q1 2025, filed 14 May 2025.